NCT05363670CompletedPhase 2
Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma
A Phase 2, Single-Dose, Randomized, Active and Placebo Controlled, Four-Period, Cross-Over Study of the Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 or Albuterol in Subjects With Persistent Asthma
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
ARS-1 is being developed for patients as a needleless alternative route of epinephrine administration for the management of refractory asthma symptoms.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 27 Apr 2022
- Start date
- 28 Jul 2022
- Primary completion date
- 2 Feb 2024
- Lead sponsor
- ARS Pharmaceuticals, Inc.
- Diseases
- Asthma
- NCT number
- NCT05363670
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 18
- From 28 Jul 2022 to the primary completion date, 2 Feb 2024
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 2\. Patients receiving beta blocker.
- 4\. Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal electrocardiogram.
- 6\. Has had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening.
Other illness
- 1\. History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition.
- 3\. Has any clinically significant medical condition or physical exam finding as deemed inappropriate by the Investigator.
- 5\. Has mucosal inflammatory disorders.
Who the study is looking for
- 1\. Is a male or female subject between the ages of 12 and 65 years, inclusive.
- 2\. Asthma that has been stable for at least four weeks prior to screening as defined by clinical history.
- 3\. Reversible bronchoconstriction.
- 4\. Has body weight more than 30 kilogram (kg) and body mass index between 18 and 34 kg/m², inclusive.
- 5\. Has no medical history of hypertension and cardiovascular disease in the last 10 years.
- 6\. At screening, has stable vital signs.
Age in the registry: 12 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Institute for Asthma and Allergy Coordinator of this site? Confirm its status | Chevy Chase | United States | Unknown status |
| Bernstein Clinical Research Center, LLC Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| University of South Florida Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.